Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Janux Therapeutics (JANX) Other Non-Current Assets (2021 - 2025)

Janux Therapeutics (JANX) has disclosed Other Non-Current Assets for 5 consecutive years, with $2.6 million as the latest value for Q4 2025.

  • Quarterly Other Non-Current Assets rose 219.61% to $2.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.6 million through Dec 2025, up 219.61% year-over-year, with the annual reading at $2.6 million for FY2025, 219.61% up from the prior year.
  • Other Non-Current Assets for Q4 2025 was $2.6 million at Janux Therapeutics, down from $2.6 million in the prior quarter.
  • The five-year high for Other Non-Current Assets was $2.7 million in Q2 2025, with the low at $140000.0 in Q3 2021.
  • Average Other Non-Current Assets over 5 years is $1.0 million, with a median of $816000.0 recorded in 2021.
  • Peak annual rise in Other Non-Current Assets hit 482.86% in 2022, while the deepest fall reached 0.0% in 2022.
  • Over 5 years, Other Non-Current Assets stood at $816000.0 in 2021, then changed by 0.0% to $816000.0 in 2022, then changed by 0.0% to $816000.0 in 2023, then changed by 0.0% to $816000.0 in 2024, then skyrocketed by 219.61% to $2.6 million in 2025.
  • According to Business Quant data, Other Non-Current Assets over the past three periods came in at $2.6 million, $2.6 million, and $2.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.